PT2771031T - Anticorpos humanizados que reconhecem a alfa-sinucleína - Google Patents
Anticorpos humanizados que reconhecem a alfa-sinucleínaInfo
- Publication number
- PT2771031T PT2771031T PT128444338T PT12844433T PT2771031T PT 2771031 T PT2771031 T PT 2771031T PT 128444338 T PT128444338 T PT 128444338T PT 12844433 T PT12844433 T PT 12844433T PT 2771031 T PT2771031 T PT 2771031T
- Authority
- PT
- Portugal
- Prior art keywords
- synuclein
- humanized antibodies
- recognize alpha
- alpha
- recognize
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161553131P | 2011-10-28 | 2011-10-28 | |
| US201261711208P | 2012-10-08 | 2012-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2771031T true PT2771031T (pt) | 2018-05-24 |
Family
ID=48168610
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT128444338T PT2771031T (pt) | 2011-10-28 | 2012-10-26 | Anticorpos humanizados que reconhecem a alfa-sinucleína |
| PT181554411T PT3378535T (pt) | 2011-10-28 | 2012-10-26 | Anticorpos humanizados que reconhecem a alfa-sinucleína |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT181554411T PT3378535T (pt) | 2011-10-28 | 2012-10-26 | Anticorpos humanizados que reconhecem a alfa-sinucleína |
Country Status (31)
| Country | Link |
|---|---|
| US (7) | US8609820B2 (pt) |
| EP (2) | EP3378535B1 (pt) |
| JP (4) | JP5775974B2 (pt) |
| KR (1) | KR101600733B1 (pt) |
| CN (2) | CN107880123A (pt) |
| AU (3) | AU2012328530A1 (pt) |
| BR (1) | BR112014010198B1 (pt) |
| CA (1) | CA2853531C (pt) |
| CL (1) | CL2014001073A1 (pt) |
| CO (1) | CO7020875A2 (pt) |
| CY (1) | CY1120398T1 (pt) |
| DK (2) | DK3378535T3 (pt) |
| ES (2) | ES2669395T3 (pt) |
| FI (1) | FI3378535T3 (pt) |
| HK (3) | HK1201450A1 (pt) |
| HR (2) | HRP20230065T1 (pt) |
| HU (2) | HUE061978T2 (pt) |
| IL (2) | IL232264B (pt) |
| LT (2) | LT2771031T (pt) |
| MX (2) | MX370234B (pt) |
| MY (1) | MY165038A (pt) |
| PE (1) | PE20141568A1 (pt) |
| PL (2) | PL3378535T3 (pt) |
| PT (2) | PT2771031T (pt) |
| RS (2) | RS63930B1 (pt) |
| RU (1) | RU2743738C2 (pt) |
| SG (1) | SG11201401857WA (pt) |
| SI (2) | SI3378535T1 (pt) |
| UA (1) | UA116194C2 (pt) |
| WO (1) | WO2013063516A1 (pt) |
| ZA (1) | ZA201403864B (pt) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9034337B2 (en) * | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| PT2771031T (pt) | 2011-10-28 | 2018-05-24 | Prothena Biosciences Ltd | Anticorpos humanizados que reconhecem a alfa-sinucleína |
| BR112014018561A8 (pt) | 2012-01-27 | 2017-07-11 | Neotope Biosciences Ltd | Anticorpo; ácido nucleico; célula hospedeira; composição farmacêutica; uso de um anticorpo; método para produção de um anticorpo; e método para produção de uma linhagem celular que produz um anticorpo |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US9856319B2 (en) * | 2012-12-28 | 2018-01-02 | Abbvie Inc. | Monovalent binding proteins |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| JP2017501848A (ja) * | 2013-11-19 | 2017-01-19 | プロセナ バイオサイエンシーズ リミテッド | 便秘症状からのレビー小体病の免疫療法のモニター |
| EP3129051A1 (en) | 2014-04-08 | 2017-02-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック， インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| EP4000632A1 (en) | 2016-06-02 | 2022-05-25 | MedImmune Limited | Antibodies to alpha-synuclein and uses thereof |
| US20180328943A1 (en) * | 2016-09-30 | 2018-11-15 | Enzo Biochem, Inc. | Immunomodulatory compositions and methods of use thereof |
| MX2019005594A (es) | 2016-11-15 | 2019-07-04 | H Lundbeck As | Agentes, usos y metodos para el tratamiento de la sinucleinopatia. |
| US11237176B2 (en) | 2016-12-02 | 2022-02-01 | Prothena Biosciences Limited | Infrared assay detecting secondary structure profiles of alpha-synuclein |
| BR112018016717A2 (pt) | 2016-12-16 | 2018-12-26 | H Lundbeck As | agentes, usos e métodos |
| US10364286B2 (en) * | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| CA3049110A1 (en) | 2017-01-06 | 2018-07-12 | Abl Bio Inc. | Anti-.alpha.-syn antibody and use thereof |
| KR102573778B1 (ko) | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
| WO2018204352A1 (en) | 2017-05-01 | 2018-11-08 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| EP3406632A1 (en) | 2017-05-23 | 2018-11-28 | S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati | Ligands binding to prion protein for use in the treatment of synucleinopathies |
| WO2019040617A1 (en) | 2017-08-23 | 2019-02-28 | The Trustees Of The University Of Pennsylvania | MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHODS USING SAME |
| CN111886251A (zh) * | 2017-12-14 | 2020-11-03 | Abl生物公司 | 抗a-syn/igf1r的双特异性抗体及其用途 |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| NL2020520B1 (en) * | 2018-03-02 | 2019-09-12 | Labo Bio Medical Invest B V | Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders |
| WO2020033756A1 (en) | 2018-08-09 | 2020-02-13 | F. Hoffmann-La Roche Ag | Determination of parkinson's disease |
| TWI734279B (zh) * | 2018-12-14 | 2021-07-21 | 美商美國禮來大藥廠 | 抗α-突觸核蛋白抗體及其用途 |
| BR112021025086A2 (pt) * | 2019-06-14 | 2022-01-25 | Abl Bio Inc | Anticorpo biespecífico contra a-syn/igfir e uso do mesmo |
| CA3178472A1 (en) | 2020-04-24 | 2021-10-28 | F. Hoffmann-La Roche Ag | Enzyme and pathway modulation with sulfhydryl compounds and their derivatives |
| CN114516914B (zh) * | 2020-11-19 | 2023-04-28 | 东莞市朋志生物科技有限公司 | 抗n末端脑钠肽前体的抗体和检测n末端脑钠肽前体的试剂和试剂盒 |
| CN112710850A (zh) * | 2020-12-29 | 2021-04-27 | 苏州百志生物科技有限公司 | 一种检测人体液中α-突触核蛋白含量的试剂盒 |
| CN113912712B (zh) * | 2021-12-15 | 2022-03-08 | 北京凯祥弘康生物科技有限公司 | 抗α-突触核蛋白的单克隆抗体的制备及其应用 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| IE64738B1 (en) | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| DE69620877T2 (de) | 1995-02-06 | 2002-12-12 | Genetics Inst | Arzneimittelformulierungen für il-12 |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| WO2000046750A1 (en) | 1999-02-05 | 2000-08-10 | Samsung Electronics Co., Ltd. | Image texture retrieving method and apparatus thereof |
| TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| GB0129260D0 (en) * | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| JP2005532825A (ja) | 2002-05-13 | 2005-11-04 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | ベネズエラウマ脳炎ウイルスに対するヒト化抗体 |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| WO2008103472A2 (en) * | 2007-02-23 | 2008-08-28 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| EP1567652B1 (de) | 2002-11-29 | 2007-08-22 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen |
| WO2004065419A1 (ja) * | 2003-01-22 | 2004-08-05 | Takeda Pharmaceutical Company Limited | 抗体およびその用途 |
| ZA200507757B (en) | 2003-04-04 | 2007-01-31 | Genentech Inc | High concentration antibody and protein formulations |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| CA2548817A1 (en) | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| US7022550B2 (en) | 2004-04-07 | 2006-04-04 | Gelcore Llc | Methods for forming aluminum-containing p-contacts for group III-nitride light emitting diodes |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| SI1820022T1 (sl) | 2004-11-10 | 2009-10-31 | Boehringer Ingelheim Pharma | Uporaba pretočne citometrične analize za optimiziranje celičnih bančnih strategij za celice CHO |
| EP1858928A2 (en) | 2005-03-08 | 2007-11-28 | Pharmacia & Upjohn Company LLC | Anti-m-csf antibody compositions having reduced levels of endotoxin |
| CA2657953A1 (en) * | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
| WO2007021255A1 (en) * | 2005-08-09 | 2007-02-22 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| SG173385A1 (en) * | 2006-07-14 | 2011-08-29 | Ac Immune S A Ch | Humanized antibody against amyloid beta |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| MX2009009080A (es) | 2007-02-23 | 2009-11-02 | Schering Corp | Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica. |
| CA2677925A1 (en) | 2007-03-02 | 2008-09-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Improvement of protein production comprising increasing the expression or activity of cert |
| AU2008228823A1 (en) | 2007-03-22 | 2008-09-25 | Imclone Llc | Stable antibody formulations |
| UA102994C2 (ru) | 2007-03-22 | 2013-09-10 | Дженентек, Инк. | АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧНО СВЯЗЫВАЕТСЯ С IgE/M1' И ИНДУЦИРУЕТ АПОПТОЗ В ЭКСПРЕССИРУЮЩИХ IgE В-КЛЕТКАХ |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| CN105126099A (zh) | 2007-12-21 | 2015-12-09 | 弗·哈夫曼-拉罗切有限公司 | 抗体制剂 |
| US7928203B2 (en) | 2007-12-28 | 2011-04-19 | Elan Pharmaceuticals, Inc. | Chimeric, humanized, or human antibody 2A4 |
| DK2282758T3 (en) * | 2008-04-29 | 2019-02-25 | Bioarctic Ab | ANTIBODIES AND VACCINES FOR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR ALPHA-SYNUCLEIN-RELATED DISORDERS |
| WO2009141239A1 (en) | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
| US20120276019A1 (en) | 2008-07-25 | 2012-11-01 | Diamedica Inc. | Tissue kallikrein for the treatment of parkinson's disease |
| SI2949666T1 (sl) * | 2008-12-19 | 2019-03-29 | Biogen International Neuroscience Gmbh | Človeška anti alfa-sinukleinska protitelesa |
| RU2733466C2 (ru) | 2009-07-28 | 2020-10-01 | Шайр Хьюман Дженетик Терапиз | Композиции и способы для лечения болезни гоше |
| PL214940B1 (pl) | 2009-07-31 | 2013-09-30 | Lozano Platonoff Alberto | Mechanizm wskaznikowy automatycznego aplikatora, zwlaszcza do insuliny |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| EP2519537A4 (en) | 2009-12-29 | 2013-07-10 | Reddys Lab Ltd Dr | CLEANING PROTEINS |
| EP2366714A1 (en) * | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| CN102939305B (zh) | 2010-04-08 | 2016-08-17 | Jn生物科学有限责任公司 | 对cd122的抗体 |
| RU2755066C2 (ru) | 2010-06-08 | 2021-09-13 | Дженентек, Инк. | Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты |
| AU2011262758B8 (en) | 2010-06-11 | 2014-09-04 | Kyowa Kirin Co., Ltd. | Anti-tim-3 antibody |
| EP3345925A3 (en) | 2010-07-15 | 2018-09-26 | Adheron Therapeutics, Inc. | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods |
| WO2012051147A1 (en) | 2010-10-11 | 2012-04-19 | Abbott Laboratories | Processes for purification of proteins |
| JP2014511174A (ja) | 2011-02-07 | 2014-05-15 | ネオトープ バイオサイエンシーズ リミテッド | Ａｐｏｅ免疫療法 |
| US8619359B2 (en) | 2011-04-27 | 2013-12-31 | Howard Letovsky | Electronic microscope filter |
| WO2012160536A1 (en) | 2011-05-26 | 2012-11-29 | Dr Reddy's Laboratories Limited | Antibody purification |
| JP6061922B2 (ja) | 2011-06-22 | 2017-01-18 | ザ ジェネラル ホスピタル コーポレイション | プロテイノパチーの処置方法 |
| SG194932A1 (en) | 2011-06-30 | 2013-12-30 | Genentech Inc | Anti-c-met antibody formulations |
| PE20141413A1 (es) | 2011-10-25 | 2014-10-25 | Onclave Therapeutics Ltd | Formulaciones de anticuerpo y metodos |
| PT2771031T (pt) | 2011-10-28 | 2018-05-24 | Prothena Biosciences Ltd | Anticorpos humanizados que reconhecem a alfa-sinucleína |
| KR20140084078A (ko) | 2011-10-31 | 2014-07-04 | 제넨테크, 인크. | 항체 제제 |
| BR112014018561A8 (pt) | 2012-01-27 | 2017-07-11 | Neotope Biosciences Ltd | Anticorpo; ácido nucleico; célula hospedeira; composição farmacêutica; uso de um anticorpo; método para produção de um anticorpo; e método para produção de uma linhagem celular que produz um anticorpo |
| SI2890712T1 (sl) | 2012-08-29 | 2019-08-30 | F. Hoffmann-La Roche Ag | Prenašalec prek krvno-možganske pregrade |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| EP3129051A1 (en) | 2014-04-08 | 2017-02-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| US10084674B2 (en) | 2015-09-09 | 2018-09-25 | International Business Machines Corporation | Virtual desktop operation and data continuity preservation |
-
2012
- 2012-10-26 PT PT128444338T patent/PT2771031T/pt unknown
- 2012-10-26 DK DK18155441.1T patent/DK3378535T3/da active
- 2012-10-26 AU AU2012328530A patent/AU2012328530A1/en not_active Abandoned
- 2012-10-26 CA CA2853531A patent/CA2853531C/en active Active
- 2012-10-26 EP EP18155441.1A patent/EP3378535B1/en active Active
- 2012-10-26 EP EP12844433.8A patent/EP2771031B1/en active Active
- 2012-10-26 UA UAA201405767A patent/UA116194C2/uk unknown
- 2012-10-26 JP JP2014539089A patent/JP5775974B2/ja active Active
- 2012-10-26 MY MYPI2014001215A patent/MY165038A/en unknown
- 2012-10-26 PT PT181554411T patent/PT3378535T/pt unknown
- 2012-10-26 HR HRP20230065TT patent/HRP20230065T1/hr unknown
- 2012-10-26 WO PCT/US2012/062290 patent/WO2013063516A1/en active Application Filing
- 2012-10-26 ES ES12844433.8T patent/ES2669395T3/es active Active
- 2012-10-26 US US13/662,261 patent/US8609820B2/en active Active
- 2012-10-26 RS RS20230054A patent/RS63930B1/sr unknown
- 2012-10-26 BR BR112014010198-1A patent/BR112014010198B1/pt active IP Right Grant
- 2012-10-26 DK DK12844433.8T patent/DK2771031T3/en active
- 2012-10-26 FI FIEP18155441.1T patent/FI3378535T3/fi active
- 2012-10-26 ES ES18155441T patent/ES2937409T3/es active Active
- 2012-10-26 LT LTEP12844433.8T patent/LT2771031T/lt unknown
- 2012-10-26 PE PE2014000613A patent/PE20141568A1/es not_active Application Discontinuation
- 2012-10-26 CN CN201711166162.2A patent/CN107880123A/zh active Pending
- 2012-10-26 PL PL18155441.1T patent/PL3378535T3/pl unknown
- 2012-10-26 KR KR1020147014374A patent/KR101600733B1/ko active IP Right Grant
- 2012-10-26 RS RS20180539A patent/RS57315B1/sr unknown
- 2012-10-26 CN CN201280053194.0A patent/CN104334184B/zh active Active
- 2012-10-26 MX MX2014005038A patent/MX370234B/es active IP Right Grant
- 2012-10-26 PL PL12844433T patent/PL2771031T3/pl unknown
- 2012-10-26 RU RU2016101137A patent/RU2743738C2/ru active
- 2012-10-26 HU HUE18155441A patent/HUE061978T2/hu unknown
- 2012-10-26 SI SI201232020T patent/SI3378535T1/sl unknown
- 2012-10-26 SI SI201231300T patent/SI2771031T1/en unknown
- 2012-10-26 LT LTEP18155441.1T patent/LT3378535T/lt unknown
- 2012-10-26 HU HUE12844433A patent/HUE037811T2/hu unknown
- 2012-10-26 SG SG11201401857WA patent/SG11201401857WA/en unknown
-
2014
- 2014-01-15 US US14/156,441 patent/US9556259B2/en active Active
- 2014-04-25 MX MX2019014658A patent/MX2019014658A/es unknown
- 2014-04-25 CL CL2014001073A patent/CL2014001073A1/es unknown
- 2014-04-27 IL IL232264A patent/IL232264B/en active IP Right Grant
- 2014-05-26 CO CO14113186A patent/CO7020875A2/es unknown
- 2014-05-27 ZA ZA2014/03864A patent/ZA201403864B/en unknown
-
2015
- 2015-02-26 HK HK15101950.9A patent/HK1201450A1/xx unknown
- 2015-07-06 JP JP2015135643A patent/JP5960328B2/ja active Active
- 2015-08-03 HK HK15107395.9A patent/HK1206637A1/xx unknown
-
2016
- 2016-04-26 AU AU2016202622A patent/AU2016202622B2/en active Active
- 2016-06-22 JP JP2016123524A patent/JP6234511B2/ja active Active
- 2016-12-21 US US15/387,580 patent/US9884906B2/en active Active
-
2017
- 2017-10-24 JP JP2017205366A patent/JP6592059B2/ja active Active
- 2017-12-14 AU AU2017276296A patent/AU2017276296B2/en active Active
- 2017-12-28 US US15/857,104 patent/US10450369B2/en active Active
-
2018
- 2018-05-10 HR HRP20180728TT patent/HRP20180728T1/hr unknown
- 2018-07-03 CY CY20181100693T patent/CY1120398T1/el unknown
- 2018-09-21 HK HK18112242.1A patent/HK1252895A1/zh unknown
-
2019
- 2019-05-20 US US16/417,309 patent/US10723792B2/en active Active
-
2020
- 2020-02-12 IL IL272615A patent/IL272615B/en unknown
- 2020-06-16 US US16/903,271 patent/US11345749B2/en active Active
-
2022
- 2022-04-26 US US17/730,074 patent/US20220411486A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1252895A1 (zh) | 識別α-突觸核蛋白的人源化抗體 | |
| HRP20180640T1 (hr) | Anti-b7-h3 antitijelo | |
| IL259826A (en) | Anti-alphabetatisiar antibody | |
| ZA201406227B (en) | Humanized antibodies that recognize alpha-synuclein | |
| ZA201400768B (en) | Interleukin-31 monoclonal antibody | |
| TWI563004B (en) | Anti-hxcr1 antibody | |
| EP2707392A4 (en) | MONOCLONAL ANTIBODY FOR ACETYLAMANTADINE | |
| EP2690111A4 (en) | MONOCLONAL ANTI-MOUSE AGGRUS ANTIBODY | |
| EP2769988A4 (en) | ANTI-GAP43 ANTIBODY | |
| HK1175486A1 (zh) | 抗腫瘤壞死因子α的人源化抗體 |